Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DCUN1D1 | Q96GG9 | 11/20 | 1.00 |
| ▸ | UBE2M | P61081 | 9/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.55 |
| ▸ | CCR2 | P41597 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18640271 | 0.86 | DCUN1D1 (1.00) | DCUN1D1UBE2MMEN1KMT2AALDH1A1 | |
| SCHEMBL18640238 | 0.77 | UBE2M (0.72) | DCUN1D1UBE2MKDM4EMEN1KMT2A | |
| SCHEMBL18640263 | 0.77 | DCUN1D1 (1.00) | DCUN1D1UBE2MMEN1KMT2AALDH1A1 | |
| SCHEMBL31499144 | 0.77 | DCUN1D1 (1.00) | DCUN1D1UBE2MMEN1KMT2AALDH1A1 | |
| SCHEMBL19638388 | 0.76 | RXFP1 (0.73) | DCUN1D1UBE2MKDM4EMEN1KMT2A | |
| SCHEMBL31435220 | 0.76 | UBE2M (0.60) | DCUN1D1UBE2MKDM4EMEN1KMT2A | |
| SCHEMBL18657586 | 0.75 | MEN1 (0.67) | DCUN1D1UBE2MKDM4EMEN1KMT2A | |
| SCHEMBL31435259 | 0.75 | UBE2M (0.59) | DCUN1D1UBE2MKDM4EMEN1KMT2A | |
| SCHEMBL25389220 | 0.75 | RXFP1 (0.74) | DCUN1D1UBE2MKDM4EALDH1A1EPHX2 | |
| SCHEMBL2239100 | 0.75 | RXFP1 (0.74) | DCUN1D1UBE2MKDM4EALDH1A1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230021224-A1 | METHODS AND COMPOSITIONS OF INHIBITING DCN1-UBC12 INTERACTION | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2023-01-19 | — | — | US | disclosed |
| US-11116757-B2 | Methods and compositions of inhibiting DCN1-UBC12 interaction | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2021-09-14 | — | — | US | disclosed |
| US-20210069172-A1 | METHODS AND COMPOSITIONS OF INHIBITING DCN1-UBC12 INTERACTION | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2021-03-11 | — | — | US | disclosed |
| WO-2017049295-A1 | METHODS AND COMPOSITIONS OF INHIBITING DCN1-UBC12 INTERACTION | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2017-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230021224-A1 | METHODS AND COMPOSITIONS OF INHIBITING DCN1-UBC12 INTERACTION | UBQLN1, CUL1, DCUN1D1 | DCUN1D1 3/4885UBE2M 8/4885KDM4E 1093/4885 |
| US-11116757-B2 | Methods and compositions of inhibiting DCN1-UBC12 interaction | UBQLN1, CUL1, DCUN1D1 | DCUN1D1 3/4885UBE2M 8/4885KDM4E 1093/4885 |
| US-20210069172-A1 | METHODS AND COMPOSITIONS OF INHIBITING DCN1-UBC12 INTERACTION | UBQLN1, CUL1, DCUN1D1 | DCUN1D1 3/4885UBE2M 8/4885KDM4E 1093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.